首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Trastuzumab pertuzumab and eribulin mesylate versus trastuzumab pertuzumab and a taxane as a first-line or second-line treatment for HER2-positive locally advanced or metastatic breast cancer: study protocol for a randomized controlled non-inferiority phase III trial in Japan (JBCRG-M06/EMERALD)

【2h】

Trastuzumab pertuzumab and eribulin mesylate versus trastuzumab pertuzumab and a taxane as a first-line or second-line treatment for HER2-positive locally advanced or metastatic breast cancer: study protocol for a randomized controlled non-inferiority phase III trial in Japan (JBCRG-M06/EMERALD)

机译：曲妥珠单抗帕妥珠单抗和甲磺酸艾瑞布林与曲妥珠单抗帕妥珠单抗和紫杉烷作为一线或二线治疗HER2阳性局部晚期或转移性乳腺癌的一线或二线治疗：III期随机对照非劣效性的研究方案在日本试用（JBCRG-M06 / EMERALD）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Study design flowchart

机译：研究设计流程图

著录项

期刊名称 Current Controlled Trials in Cardiovascular Medicine
作者
Toshinari Yamashita; Norikazu Masuda; Shigehira Saji; Kazuhiro Araki; Yoshinori Ito; Toshimi Takano; Masato Takahashi; Junji Tsurutani; Kei Koizumi; Masahiro Kitada; Yasuyuki Kojima; Yasuaki Sagara; Hiroshi Tada; Tsutomu Iwasa; Takayuki Kadoya; Tsuguo Iwatani; Hiroki Hasegawa; Satoshi Morita; Shinji Ohno;
展开▼
作者单位

展开▼
年(卷),期 2020(21),-1
年度 2020
页码 -1
总页数 9
原文格式 PDF
正文语种
中图分类心血管疾病;
关键词
Metastatic breast cancer; HER2-positive; Non-inferiority; Eribulin; Taxane; Trastuzumab; Pertuzumab; Combination therapy;

机译：转移性乳腺癌;HER2阳性;非自卑性;依立布林;塔克烷;曲妥珠单抗;培妥珠单抗;联合治疗;
入库时间 2022-08-21 11:37:38

相似文献

外文文献
中文文献
专利

1. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [J] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, Trials . 2020,第1期

机译：Trastuzumab，Pertuzumab和Eribulin甲磺酸丁酯与曲妥珠单抗，Pertuzumab和紫罗兰作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势，III期的研究方案日本试验（JBCRG-M06 / Emerald）
2. A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study [J] . Yamamoto Yutaka, Iwata Hiroji, Ueno Takayuki, Japanese journal of clinical oncology. . 2018,第9期

机译：在Her2阳性局部晚期/转移性乳腺癌患者中，Hertuzumab患者的随机开放标签，腹部疗法试验，曲妥珠单抗和化疗：日本乳腺癌研究组-M05珍贵研究
3. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA) [J] . MilesD., BaselgaJ., AmadoriD., Breast cancer research and treatment. . 2013,第1期

机译：帕妥珠单抗，曲妥珠单抗和多西他赛治疗HER2阳性转移性乳腺癌的老年患者：亚组分析来自一项随机，双盲，安慰剂对照的III期临床试验（CLEOPATRA）
4. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
5. Correction to: Trastuzumab pertuzumab and eribulin mesylate versus trastuzumab pertuzumab and a taxane as a first-line or second-line treatment for HER2-positive locally advanced or metastatic breast cancer: study protocol for a randomized controlled non-inferiority phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：校正至：曲妥珠单抗帕妥珠单抗和甲磺酸艾瑞布林与曲妥珠单抗帕妥珠单抗和紫杉烷作为HER2阳性局部晚期或转移性乳腺癌的一线或二线治疗：随机对照非劣效性的研究方案日本的III期试验（JBCRG-M06 / EMERALD）
6. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：校正至：Trastuzumab，Pertuzumab和Eribulin甲蛋白与曲妥珠单抗，Pertuzumab和紫杉烷作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势的研究方案，日本第三阶段试验（JBCRG-M06 / Emerald）

Trastuzumab pertuzumab and eribulin mesylate versus trastuzumab pertuzumab and a taxane as a first-line or second-line treatment for HER2-positive locally advanced or metastatic breast cancer: study protocol for a randomized controlled non-inferiority phase III trial in Japan (JBCRG-M06/EMERALD)

摘要

著录项

相似文献

相关主题

期刊订阅